Net Income

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

A Nasdaq firm is using AI real estate software profits to build a massive Solana treasury. Capital Currents unpacks DFDV's radical dual-pronged strategy.

Baxter is buying back billions in debt, a strategic move to clean its balance sheet. But with operational issues mounting, is it enough to win back investors?

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.

With its CFO departing after a major strategic pivot, AAR CORP. names a 13-year insider as his interim replacement. What does this signal for investors?

With $15M in new funding and seasoned mining execs on board, Getty Copper is now debt-free and poised to unlock the potential of its vast copper assets.

Promising Phase 3 data reveals a novel, organ-sparing laser therapy for a rare cancer, signaling a potential paradigm shift away from radical surgery.

Bitwise appoints a new data VP amid a frenzied AI market. But can one leader bridge the gap between massive spending and measurable business results?

A class action lawsuit against Telix Pharmaceuticals reveals the perilous gap between optimistic corporate disclosures and harsh regulatory setbacks.

While official data points to growth, new metrics reveal nearly 25% of workers are functionally unemployed, exposing a deep affordability crisis.

A promising fintech's complex arbitrage strategy collapses, triggering a stock crash, CEO exit, and a wave of securities fraud investigations.

MicroCloud Hologram is betting $400M on a quantum-driven 3D model. Is it a revolutionary leap for digital creation or a costly gamble on unproven tech?

A last-minute regulatory filing by Balyasny Asset Management pulls back the curtain on the multi-billion-dollar battle for Spectris, a key health tech enabler.

How Winemaker of the Year Jesse Katz blends record-setting sales, historic vineyards, and philanthropy to disrupt the ultra-premium wine market.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

The battery innovator secures fresh capital to scale its 'One-Pot' process. We analyze if this move signals a turning point for investors and the EV market.

Praxie has launched a no-code AI platform empowering managers to build their own solutions, tackling the complexity and cost that plague enterprise AI.

From AI-powered planning to exclusive lounges and hidden gem destinations, discover the trends reshaping how we'll travel and spend in 2026.

A major CRO presents 10 pivotal studies at the world's top blood disease meeting, revealing a strategy built on real-world data and collaborative innovation.